We report on the formation of a triazolopyrimidine derivative ligand, 7-amino-5-methyl-1,2,4-triazolo[1,5-a]pyrimidine (7-amtp), and a new family of coordination compounds based on this ligand and zinc as metal ion, synthesized by conventional routes. These materials possess different mononuclear structures, namely [ZnCl₂(7-amtp)₂] (1), [Zn(7-amtp)₂(H₂O)₄](NO₃)₂·2(7-amtp)·6H₂O (2) and [Zn(7-amtp)₂(H₂O)₄](SO₄)·1.5H₂O (3) derived from the use of different zinc (II) salts, in such a way that the counterions govern the crystallization to a large extent. These compounds present and show variable luminescent properties based on ligand-centred charge transfers which have been deeply studied by Time Dependent Density Functional Theory (TD-DFT) calculations. When these compounds are transferred to solution, preserving complex entities as corroborated by NMR studies, they present interesting anti-diabetic and anti-parasitic capabilities, with a comparatively higher selectivity index than other previously reported triazolopyrimidine-based materials. The results derived from in vivo experiments conducted in mice also confirm their promising activity as anti-diabetic drug being capable of dropping glucose levels after oral administration. Therefore, these new materials may be considered as excellent candidates to be further investigated in the field of luminescent coordination compounds with biomedical applications.

我们报告了三唑并嘧啶衍生物配体、7-氨基-5-甲基-1,2,4-三唑并[1,5- a ]嘧啶（7-amtp）的形成，以及基于该配体的新系列配位化合物配体和锌作为金属离子，通过常规途径合成。这些材料具有不同的单核结构，即[ZnCl ₂ (7-amtp) ₂ ] ( 1 )、[Zn(7-amtp) ₂ (H ₂ O) ₄ ](NO ₃ ) ₂ ·2(7-amtp)· 6H ₂ O ( 2 ) 和[Zn(7-amtp) ₂ (H ₂ O) ₄ ](SO ₄ )·1.5H ₂ O (3) 源自使用不同的锌 (II) 盐，因此抗衡离子在很大程度上控制着结晶。这些化合物呈现并显示出基于配体中心电荷转移的可变发光特性，这些特性已通过时间相关密度泛函理论 (TD-DFT) 计算进行了深入研究。当这些化合物被转移到溶液中时，保留复杂实体，如核磁共振研究所证实的那样，它们表现出有趣的抗糖尿病和抗寄生虫能力，与其他先前报道的基于三唑并嘧啶的材料相比具有相对更高的选择性指数。来自小鼠体内实验的结果也证实了它们作为抗糖尿病药物的有希望的活性，能够在口服后降低葡萄糖水平。所以，